Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressureinduced transient ischemic injury
Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressureinduced transient ischemic injury
Madeira MH, Boia R, Elvas F, Martins T, Cunha RA, Ambrósio AF, Santiago AR
Translational Research 2016; 169:112128
2016
Inside the Diabetic Brain: Role of Different Players Involved in Cognitive Decline
Inside the Diabetic Brain: Role of Different Players Involved in Cognitive Decline
Gaspar JM, Baptista FI, Macedo MP, Ambrosio AF
ACS Chem. Neurosci. 2016; 7, 131−142
2016
Therapeutic Opportunities for Caffeine and A 2A Receptor Antagonists in Retinal Diseases
Therapeutic Opportunities for Caffeine and A 2A Receptor Antagonists in Retinal Diseases
Boia R, Ambrósio AF, Santiago AR
Ophthalmic Res. 2016; 55:212218
2016
Protective Effect of a GLP-1 Analog on Ischemia- Reperfusion Induced BloodRetinal Barrier Breakdown and Inflammation
Protective Effect of a GLP-1 Analog on Ischemia- Reperfusion Induced BloodRetinal Barrier Breakdown and Inflammation
A Gonçalves, CM Lin, A. Muthusamy, C Fontes-Ribeiro, AF Ambrósio, SF Abcouwer, R Fernandes and DA Antonetti
Invest Ophthalmol Vis Sci. 2016;57:25842592. DOI:10.1167/iovs.15-19006
2016
Caffeine administration prevents retinal neuroinflammation and loss of retinal ganglion cells in an animal model of glaucoma
Caffeine administration prevents retinal neuroinflammation and loss of retinal ganglion cells in an animal model of glaucoma
MH Madeira, A Ortin-Martinez, F Nadal-Nícolas, AF Ambrósio, M Vidal-Sanz, M Agudo-Barriuso and AR Santiago
Scientific Reports. 6:27532. DOI: 10.1038/srep27532
2016
The Adenosinergic System in Diabetic Retinopathy
The Adenosinergic System in Diabetic Retinopathy
J Vindeirinho, AR Santiago, C Cavadas, A F Ambrósio and P F Santos
Volume 2016 (2016), Article ID 4270301, 8 pages
2016
Modeling Human Glaucoma: Lessons from the in vitro Models
Modeling Human Glaucoma: Lessons from the in vitro Models
Aires I, Ambrósio AF, Santiago AR
Ophthalmic Res. 2016. DOI: 10.1159/000448480
2016
Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial
Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial
Trento M, Durando O, Lavecchia S, Charrier L, Cavallo F, Costa MA, Hernández C, Simó R, Porta M, for the EUROCONDOR trial investigators.
Endocrine DOI 10.1007/s12020-016-1097-0
2016
Correlation between Retinal Vessel Calibre and Neurodegeneration in Patients with Type 2 Diabetes Mellitus in the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)
Correlation between Retinal Vessel Calibre and Neurodegeneration in Patients with Type 2 Diabetes Mellitus in the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)
Frydkjaer-Olsen U, Hansen RS, Simó R, Cunha-Vaz J, Peto T, Grauslund J on behalf of the EUROCONDOR
Ophthalmic Res. 2016;56:10-16. DOI: 10.1159/000444396
2016
Machine Learning Techniques in Clinical Vision Sciences, Current Eye Research
Machine Learning Techniques in Clinical Vision Sciences, Current Eye Research
Caixinha M, Nunes S
ISSN: 0271-3683 (Print) 1460-2202 (Online) Journal homepage: http://www.tandfonline.com/loi/icey20
2016
Associations with intraocular pressure across Europe: The European Eye Epidemiology (E3) Consortium
Associations with intraocular pressure across Europe: The European Eye Epidemiology (E3) Consortium
Khawaja1 AP, Springelkamp H, Creuzot-Garcher C, Delcourt C, Hofman A, Höhn R, Iglesias AI, Wolfs RCW, Jean-François Korobelnik, Silva R, Topouzis F, Williams KM, Bron AM, Buitendijk GHS, da Luz Cachulo M, Cougnard-Gregoire A, Jean-François Dartigues, Hammond C, Pfeiffer N, Salonikiou A, van Duijn CM, Vingerling JR, Luben RN, Mirshahi A, Lamparter J, Klaver CCW, Jansonius NM, Foster PJ, On behalf of the European Eye Epidemiology (E3) Consortium.
Eur J Epidemiol DOI 10.1007/s10654-016-0191-1
2016
Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial
Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial
Trento M, Durando O, Lavecchia S, Charrier L, Cavallo F, Costa MA, Hernández C, Simó R, Porta M, for the EUROCONDOR trial investigators.
Endocrine DOI 10.1007/s12020-016-1097-0
2016
Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.
Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.
Mendes D, Alves C, Batel Marques F.
OBJECTIVE:
To explore the usefulness of number needed to treat to be harmed (NNTH), in benefit-risk assessments, by studying the agreement between NNTH values and withdrawals of medicines from European market due to safety reasons.
METHODS:
Medicines with data from longitudinal studies were included. Studies were identified from European Medicines Agency’s Reports. Meta-analyses were performed to pool odds ratios (OR) with 95% confidence-intervals (CI). Published control event rates were applied to ORs to calculate NNTHs (95%CI) for selected adverse events.
RESULTS:
NNTH (95%CI) decreased from pre- to post-marketing for the eight medicines included: peripheral neuropathy (∞ vs. 12[non-significant; NS] with almitrine; heart valve disease with benfluorex (∞ vs. NNTH ranging from 7[4-13] to 7[5-9]); myopathy (-4096[NS] vs. 797[421-1690]), new-onset diabetes (113[NS] vs. 390[425-778]), bleeding (∞ vs. 517[317-1153]), and infection (∞ vs. 253[164-463]) with niacin-laropiprant; psychiatric disorders (12[7-34] vs. 9[5-24]) with rimonabant; myocardial infarction (MI) [-1305 vs. 270[89-4362]) with rofecoxib; MI (-510 vs. NNTH ranging from 152[55-4003] to 568[344-1350]) with rosiglitazone; cardiovascular events (∞ vs. 245[129-1318]) with sibutramine; and liver injury (∞ vs. 5957[NS]) with ximelagatran.
CONCLUSION:
NNTH have potential of use as a supportive tool in benefit-risk re-evaluations of medicines and may help regulators to making decisions on drug safety.
Expert Opin Drug Saf. 2016 Jul 28;15(10):1301-12. doi: 10.1080/14740338.2016.1217989
2016
http://www.ncbi.nlm.nih.gov/pubmed/27467204
Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis
Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis
Alves C, Ribeiro I, Penedones A, Mendes D, Batel Marques F
Ophthalmic Res. 2016 Jul 13;57(1):60-69. DOI:10.1159/000446845
2017
https://www.karger.com/Article/Abstract/446845
Drug Transport Across Blood-Ocular Barriers and Pharmacokinetics
Drug Transport Across Blood-Ocular Barriers and Pharmacokinetics
Cunha-Vaz J, Batel Marques F, Fernandes R, Alves C, Velpandian T
Pharmacology of Ocular Therapeutics, Edition: 1st, Chapter: 3. Drug Transport Across Blood-Ocular Barriers and Pharmacokinetics, Publisher: Springer International, Editors: Thirumurthy Velpandian, pp.37-63
2016
Comparison of preservative – free latanoprost and bimatoprost in a multicenter, randomized, investigator – masked cross- over clinical trial, the SPORT trial
Comparison of preservative – free latanoprost and bimatoprost in a multicenter, randomized, investigator – masked cross- over clinical trial, the SPORT trial
Stalmans I, Oddone F, Cordeiro MF, Hommer A, Montesano G, Ribeiro L, Mégevand GS, Rossetti L for the EVICR.net.
Graefes Arch Clin Exp Ophthalmol DOI 10.1007/s00417-016-3299-9
2016
Age-related Macular Degeneration in Portugal: prevalence and risk factors in a coastal and an inland town. The Coimbra Eye Study Report 2
Age-related Macular Degeneration in Portugal: prevalence and risk factors in a coastal and an inland town. The Coimbra Eye Study Report 2
M. Cachulo, I. Laíns, C. Lobo, J. Figueira, L. Ribeiro, J. P. Marques, J. Costa, A. Vieira, J. Rodrigues, D. Alves, S. Nunes, M. Costa, V. Rodrigues, J. Cunha-Vaz, C. Delcourt, R. Silva
Acta Ophthalmol. 2016 Sep;94(6):e442-53. doi: 10.1111/aos.12950.
2016
A systematic review and meta-analysis of the association between systemic fluoroquinolones and retinal detachment.
A systematic review and meta-analysis of the association between systemic fluoroquinolones and retinal detachment.
Carlos Alves, Ana Penedones, Diogo Mendes and Francisco Batel Marques
Acta Ophthalmol. 2016 Feb 5. doi: 10.1111/aos.12931.
2016
http://onlinelibrary.wiley.com/doi/10.1111/aos.12931/abstract;jsessionid=0857755765BEDB9128402C8C786E8567.f01t02
Simulation of Cellular Changes on Optical Coherence Tomography of Human Retina
Simulation of Cellular Changes on Optical Coherence Tomography of Human Retina
M. Santos, A. Araújo, S. Barbeiro, F. Caramelo, A. Correia, M. Marques, L. Pinto, P. Serranho, R. Bernardes, M. Morgado
Engineering in Medicine and Biology Society (EMBC), 37th Annual International Conference of the IEEE (2015), 8147-8150, DOI: 10.1109/EMBC.2015.7320285
2015
Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure
Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure
M. Madeira, F. Elvas, R. Boia, F. Gonçalves, R. Cunha, A. Ambrósio, A. Santiago
Journal of Neuroinflammation (2015) 12:115 DOI 10.1186/s12974-015-0333-5
2015